Fund shareholders of Theravance Biopharma Inc
ISIN KYG8807B1068 · United States · LEI 5493007VTSXP4Z6MIW52
- Fund shareholders
- 207
- Of which ETFs
- 58 149 other funds
- Value held
- 163.7M $
- Share of capital
- 18.9 % of 51.9M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 73 | 1.2K $ | 0.04 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 70 | 1.2K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 53 | 860.2 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 39 | 711.8 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Dimensional US Vector Equity ETF Dimensional ETF Trust | 16 | 267.8 $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 13 | 237.3 $ | 0.02 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 10 | 162.3 $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Invesco Biotechnology & Genome ETF Invesco Exchange-Traded Fund Trust | 2.50 % | as of Apr 30, 2026 ↗ |
| Virtus Biotech Etf ETFis Series Trust I | 1.47 % | as of Apr 30, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 1.42 % | as of Mar 31, 2026 ↗ |
| PROFUND VP PHARMACEUTICALS ProFunds | 1.36 % | as of Mar 31, 2026 ↗ |
| Direxion Daily Pharmaceutical & Medical Bull 3X Shares Direxion Shares ETF Trust | 1.02 % | as of Apr 30, 2026 ↗ |
| PHARMACEUTICALS ULTRASECTOR PROFUND ProFunds | 1.00 % | as of Apr 30, 2026 ↗ |
| Inspire Fidelis Multi Factor ETF Northern Lights Fund Trust IV | 0.90 % | as of Feb 28, 2026 ↗ |
| JAMES MICRO CAP FUND JAMES ADVANTAGE FUNDS | 0.81 % | as of Mar 31, 2026 ↗ |
| Janus Henderson Small Cap Growth Alpha ETF Janus Detroit Street Trust | 0.73 % | as of Apr 30, 2026 ↗ |
| Franklin U.S. Small Cap Equity Fund Legg Mason Global Asset Management Trust | 0.65 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 207 | +15 | 9,790,825 | +20.2 % |
| 2026Q1 | 192 | +25 | 8,144,301 | +11.3 % |
| 2025Q4 | 167 | +21 | 7,318,369 | +4.1 % |
| 2025Q3 | 146 | +12 | 7,028,073 | +0.2 % |
| 2025Q2 | 134 | 0 | 7,010,942 | -1.3 % |
| 2025Q1 | 134 | -5 | 7,103,697 | -1.1 % |
| 2024Q4 | 139 | 0 | 7,185,661 | -3.6 % |
| 2024Q3 | 139 | -5 | 7,456,430 | -7.9 % |
| 2024Q2 | 144 | +6 | 8,093,512 | -10.4 % |
| 2024Q1 | 138 | +5 | 9,030,516 | -4.9 % |
| 2023Q4 | 133 | 9,499,419 |
Cite this page
Titelia. "Fund shareholders of Theravance Biopharma Inc". https://titelia.com/en/stocks/theravance-biopharma-inc-KYG8807B1068